Drug updated on 7/25/2024
Dosage Form | Injection (intravenous; 50 mg, 100 mg) |
Drug Class | Tetracycline class antibacterials |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Eravacycline (Xerava) is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
- The information was derived from a total of five systematic reviews/meta-analyses.
- In comparison to carbapenems, eravacycline shows no significant difference in clinical cure rates across various populations, including clinically evaluable, microbiologically evaluable, and modified intention-to-treat groups.
- Safety profiles indicate that eravacycline has similar rates of adverse events compared to carbapenems but may have higher odds for minor adverse events like nausea; however, it does not significantly differ in serious adverse events or discontinuation due to side effects.
- Subgroup analysis highlights that most studies involved lower-risk patients with APACHE II scores <10. Specific data on concurrent bacteremia showed promising results for eravacycline's effectiveness and safety comparable to carbapenem treatments.
- Overall findings suggest that while cefepime plus metronidazole might be more efficacious as an empirical treatment option, eravacycline remains a viable alternative, particularly as a carbapenem-sparing agent.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Xerava (eravacycline) Prescribing Information. | 2021 | Tetraphase Pharmaceuticals Inc, Watertown, MA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials. | 2023 | International Journal of Antimicrobial Agents |
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis. | 2023 | BMC Infectious Diseases |
Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: a network meta-analysis of randomised clinical trials. | 2023 | Journal of Global Antimicrobial Resistance |
Efficacy and safety of eravacycline: a meta-analysis. | 2021 | Journal of Global Antimicrobial Resistance |
Efficacy and tolerability of eravacycline in bacteremic patients with complicated intra-abdominal infection: a pooled analysis from the IGNITE1 and IGNITE4 studies. | 2021 | Surgical Infections |